Research Paper Volume 13, Issue 16 pp 20793—20807
Stimulator of interferon response cGAMP interactor overcomes ERBB2-mediated apatinib resistance in head and neck squamous cell carcinoma
Figure 3. The combination of lapatinib and apatinib re-sensitizes AR cells to apatinib (A) The negative correlation between ERBB2 and TILs was confirmed using TIMER 2.0. (B) Cell viability after apatinib (20 μM) treatment, with or without lapatinib (20 μM), for different times, as assessed using an MTT assay. The combination of lapatinib and apatinib re-sensitized AR cells to apatinib. (C) Colony formation was inhibited in the combination group compared with that in the groups treated with each drug alone. (D) Western blotting illustrating the abundance of related signaling pathway proteins after apatinib (20 μM) treatment, with or without lapatinib(20 μM). Lapatinib treatment suppressed the levels of ERRB2, AKT and ERK phosphorylation. *P < 0.05, **P < 0.01, ***P < 0.001 versus the control.